Published in Proc Natl Acad Sci U S A on January 23, 2001
ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J Virol (2005) 2.36
Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. Mol Biol Cell (2005) 2.36
Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins. J Virol (2002) 1.67
Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther (2012) 1.44
Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein. EMBO J (2003) 1.26
Potential roles for ubiquitin and the proteasome during ribosome biogenesis. Mol Cell Biol (2006) 1.25
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. Mol Cell Biol (2008) 1.17
Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition. Mol Cell Proteomics (2009) 1.05
MRPS18-2 protein immortalizes primary rat embryonic fibroblasts and endows them with stem cell-like properties. Proc Natl Acad Sci U S A (2009) 0.95
Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem J (2005) 0.95
Myeloma cells contain high levels of inorganic polyphosphate which is associated with nucleolar transcription. Haematologica (2012) 0.94
Localization of proteasomes and proteasomal proteolysis in the mammalian interphase cell nucleus by systematic application of immunocytochemistry. Histochem Cell Biol (2007) 0.93
Dictyostelium discoideum has a highly Q/N-rich proteome and shows an unusual resilience to protein aggregation. Proc Natl Acad Sci U S A (2015) 0.93
The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition. Cell Death Differ (2011) 0.91
Post-translational modifications of PML: consequences and implications. Front Oncol (2013) 0.88
Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One (2011) 0.87
Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85
Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol (2009) 0.85
Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus. J Biol Chem (2013) 0.85
Evidence for ubiquitin-regulated nuclear and subnuclear trafficking among Paramyxovirinae matrix proteins. PLoS Pathog (2015) 0.85
Nuclear import of an intact preassembled proteasome particle. Mol Biol Cell (2011) 0.83
N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies. J Cell Sci (2010) 0.83
The nucleolar detention pathway: A cellular strategy for regulating molecular networks. Cell Cycle (2012) 0.82
Multiphoton ANS fluorescence microscopy as an in vivo sensor for protein misfolding stress. Cell Stress Chaperones (2011) 0.81
The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis. Hum Mol Genet (2012) 0.81
Subcellular distribution of human RDM1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stress. Nucleic Acids Res (2007) 0.81
p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol Cancer (2003) 0.80
Proteasome activity influences UV-mediated subnuclear localization changes of NPM. PLoS One (2013) 0.79
Human promyelocytic leukemia protein is targeted to distinct subnuclear domains in plant nuclei and colocalizes with nucleolar constituents in a SUMO-dependent manner. FEBS Open Bio (2016) 0.76
Nucleolar stress induces ubiquitination-independent proteasomal degradation of PICT1 protein. J Biol Chem (2014) 0.76
Immunofluorescent localization of ubiquitin and proteasomes in nucleolar vacuoles of soybean root meristematic cells. Eur J Histochem (2012) 0.76
PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol Cancer (2009) 0.75
The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies. Nucleus (2015) 0.75
Aggresomes: a cellular response to misfolded proteins. J Cell Biol (1998) 11.24
Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol (1998) 7.27
The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J (1998) 6.37
Structure and function in the nucleus. Science (1998) 6.26
Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J (1998) 5.15
The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol (1998) 4.43
The plurifunctional nucleolus. Nucleic Acids Res (1998) 4.11
Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 4.05
Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell (1985) 3.72
Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene (1999) 3.41
Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 3.22
Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol (1997) 2.98
The nucleolus: an old factory with unexpected capabilities. Trends Cell Biol (2000) 2.97
PML induces a novel caspase-independent death process. Nat Genet (1998) 2.66
SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci (1999) 2.46
Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol (1998) 2.26
A constitutive nucleolar protein identified as a member of the nucleoplasmin family. EMBO J (1987) 2.20
Dynamics of proteasome distribution in living cells. EMBO J (1997) 2.18
Intracellular localization of proteasomal degradation of a viral antigen. J Cell Biol (1999) 2.04
Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J (2000) 1.80
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J (1997) 1.65
Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet (1998) 1.64
The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol (1996) 1.61
Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur J Cell Biol (1996) 1.42
The PML nuclear bodies: actors or extras? Curr Opin Genet Dev (1999) 1.40
Reversible nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 and hsp70 proteins after exposure to heat shock or cell density congestion. J Gen Virol (1995) 1.17
Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. J Gen Virol (2001) 1.00
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (2006) 7.88
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 5.58
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell (1983) 4.22
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Suppression of malignancy by cell fusion. Nature (1969) 3.41
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer (1971) 3.00
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer (1972) 2.80
Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res (1982) 2.68
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
EB virus-induced B lymphocyte cell lines producing specific antibody. Nature (1977) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
Contrasting patterns of retinoblastoma protein expression in mouse embryonic stem cells and embryonic fibroblasts. Oncogene (1994) 2.46
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol (1979) 2.31
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Linear association between cellular DNA and Epstein-Barr virus DNA in a human lymphoblastoid cell line. Proc Natl Acad Sci U S A (1973) 2.27
Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst (1973) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Tumor antigens. Annu Rev Microbiol (1966) 2.19
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines. Int J Cancer (1971) 2.18
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome. Int J Cancer (1973) 2.14
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A (1988) 2.12
Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10
Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature (1976) 2.10
Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol (1980) 2.07
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1973) 2.02
Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. Cancer Res (1967) 2.01
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer (1975) 1.95
Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med (1984) 1.94
A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics (1972) 1.93
Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene (1993) 1.91
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector. Gene (1986) 1.90
Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci U S A (1979) 1.90
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer (1977) 1.84
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med (1985) 1.83
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer (1976) 1.81
Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice. Int J Cancer (1973) 1.80
Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood (2000) 1.78
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A (1988) 1.76
Immunological factors affecting tumour growth. Br Med J (1970) 1.75
Solubilization of the Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA-binding protein. J Virol (1977) 1.75
Herpesviruses and oncogenesis. Proc Natl Acad Sci U S A (1972) 1.74
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A (1994) 1.74
The Epstein-Barr virus and neoplasia. N Engl J Med (1975) 1.72
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol (1969) 1.68
Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology (1971) 1.68
Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells. J Virol (1985) 1.66
Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines. J Virol (1978) 1.65
Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol (1991) 1.65
Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A (1987) 1.63
The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol (1996) 1.61
Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst (1966) 1.61
Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture. Cancer Res (1968) 1.61